FIGURE 2.

Genomic features in ctDNA facilitated the early detection of disease progression during HER2‐targeted therapy. (A) The real‐time changes of ctDNA features (ERBB2 copy number, total copy number load [TCL], and tumor mutation burden [TMB]) and CEA for 30 patients who ever reached progressed disease (PD). Computed tomography (CT)‐based PD, ctDNA‐based PD, and CEA‐based PD were marked by separate vertical lines. (B) The advancement of ctDNA‐based PD and CEA‐based PD compared with CT‐based PD in detecting disease progressions for the 30 patients received HER2‐targeted therapy. (C) CT‐scanned images for three representative cases were displayed to compare ctDNA‐based PD with CT‐based PD